natgillin/translations-raw huggingface dataset:
The outer layer is beige and labelled with the following: - “Prometax”, “4.6 mg/24 h” and “AMCX”, - “Prometax”, “9.5 mg/24 h” and “BHDI”, - “Prometax”, “13.3 mg/24 h” and “CNFU”. 
Zunanja plast je rjavkasto bele barve z eno od naslednjih oznak: - “Prometax”, “4.6 mg/24 h” in “AMCX”, - “Prometax”, “9.5 mg/24 h” in “BHDI”, - “Prometax”, “13.3 mg/24 h” in “CNFU”.
56 hard capsules 
56 trdih kapsul
FOLDING BOX AND BOTTLE LABEL 
NALEPKA NA ŠKATLI IN STEKLENICI
What you need to know before you use Prometax 
Kaj morate vedeti, preden boste uporabili zdravilo Prometax
95% CI p-value 
DLSM 95% IZ
7 transdermal patches 30 transdermal patches 
7 transdermalnih obližev 30 transdermalnih obližev
If you are pregnant, the benefits of using Prometax must be assessed against the possible effects on your unborn child. Prometax should not be used during pregnancy unless clearly necessary. 
V primeru, da ste noseči, je treba pretehtati koristi uporabe zdravila Prometax in možne učinke na nerojenega otroka.
Alpha-tocopherol Silicone oil Dimethicone 
Adhezivni matriks zdravila α-tokoferol silikonsko olje dimetikon
Attaching the syringe to the bottle 
Nameščanje brizge na steklenico
Each patch is sealed in a sachet that protects it until you are ready to put it on. Do not open the sachet or remove a patch until just before you apply it. 
Vsak obliž je zaprt v vrečki, ki ga ščiti, dokler ga ne želite namestiti.
• Fainting or accidentally falling 
• omedlevica ali nezgodni padci
What you need to know before you take Prometax 
Kaj morate vedeti, preden boste vzeli zdravilo Prometax
No dose adjustment is necessary in patients with renal impairment (see section 4.2). 
Pri bolnikih z okvaro ledvic prilagajanje odmerkov ni potrebno (glejte poglavje 4.2).
• Do not use this medicine after the expiry date which is stated on the carton and sachet after EXP. 
• Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in vrečki poleg oznake EXP. Rok uporabnosti zdravila se izteče na zadnji dan navedenega meseca.
Rivastigmine was not mutagenic in a standard battery of in vitro and in vivo tests, except in a chromosomal aberration test in human peripheral lymphocytes at a dose exceeding 10 
V standardni bateriji testov in vitro in in vivo rivastigmin ni bil mutagen, razen v testu kromosomskih aberacij v človeških perifernih levkocitih v odmerku, ki je 104-krat presegal dotedanjo klinično izpostavljenost.
Your doctor will also monitor your weight whilst you are taking this medicine. 
V času jemanja tega zdravila bo zdravnik spremljal tudi vašo telesno maso.
Patients with severe hepatic impairment have not been studied, however, Prometax capsules may be used in this patient population provided close monitoring is exercised (see sections 4.4 and 5.2). 
Uporabe zdravila pri bolnikih s težko jetrno okvaro niso proučili, bolniki iz te populacije lahko kljub temu uporabljajo zdravilo Prometax v obliki kapsul, vendar jih je treba skrbno spremljati (glejte poglavji 4.4 in 5.2).
ITT + RDO population (n=87) 
Skupina ITT + RDO (n=87)
After switching to 4.6 mg/24 h transdermal patches, provided these are well tolerated after a minimum of four weeks of treatment, the dose of 4.6 mg/24 h should be increased to 9.5 mg/24 h, which is the recommended effective dose. 
Če bolnik po prehodu na zdravljenje s transdermalnimi obliži 4,6 mg/24 h ta odmerek dobro prenaša, je treba po najmanj štirih tednih zvišati odmerek s 4,6 mg/24 h na 9,5 mg/24 h, kar je priporočeni učinkoviti odmerek.
One of the inactive ingredients in Prometax oral solution is sodium benzoate. 
Ena od neaktivnih sestavin peroralne raztopine Prometax je natrijev benzoat.
These include the ADAS-Cog (Alzheimer's Disease Assessment Scale - Cognitive subscale, a performance based measure of cognition), the CIBIC-Plus (Clinician's Interview Based Impression of Change-Plus, a comprehensive global assessment of the patient by the physician incorporating caregiver input), and the PDS (Progressive Deterioration Scale, a caregiver-rated assessment of the activities of daily living including personal hygiene, feeding, dressing, household chores such as shopping, retention of ability to orient oneself to surroundings as well as involvement in activities relating to finances, etc.). 
Med njimi so ADAS-Cog (Alzheimer's Disease Assessment Scale - Cognitive subscale, Lestvica za oceno kognitivnih sposobnosti bolnikov z Alzheimerjevo boleznijo, merilo kognitivne zmogljivosti, ki temelji na izvrševanju aktivnosti), CIBIC-Plus (Clinician's Interview Based Impression of ChangePlus, Zdravnikova ocena spremembe bolezni na podlagi pogovora, celostno globalno ocenjevanje bolnika, ki ga opravlja zdravnik in ki zajema tudi podatke, ki jih daje/-jo negovalec/-ci) in PDS (Progressive Deterioration Scale, Lestvica progresivnega slabšanja, negovalčeva ocena vsakodnevnih aktivnosti, na primer osebne higiene, hranjenja, oblačenja, gospodinjskih opravil, na primer nakupovanja, ohranjanje zmožnosti orientacije v okolju, pa tudi ukvarjanje z denarnimi zadevami itn.).
• Keep the transdermal patch in the sachet until use. 
• Pred uporabo shranjujte transdermalni obliž v vrečki.
• Renal impairment: No dose adjustment is necessary for patients with renal impairment (see section 5.2). 
• Okvara ledvic: Pri bolnikih z okvaro ledvic ni potrebno prilagajati odmerjanja (glejte poglavje
Cardiac arrhythmia (e.g. bradycardia, atrio-ventricular block, atrial fibrillation and tachycardia) 
Srčne bolezni redki angina pektoris zelo redki srčne aritmije (npr. bradikardija, atrioventrikularni blok, atrijska fibrilacija in tahikardija)
The following additional adverse reactions have been observed with Prometax transdermal patches: delirium, pyrexia, decreased appetite, urinary incontinence (common), psychomotor hyperactivity (uncommon), erythema, urticaria, vesicles, allergic dermatitis (not known). 
Pri uporabi transdermalnih obližev Prometax so dodatno opažali še naslednje neželene učinke: delirij, zvišano telesno temperaturo, zmanjšan apetit, urinska inkontinenca (pogosto), psihomotorična hiperaktivnost (občasno), eritem, urtikarija, mehurčki, alergijski dermatitis (pogostnost neznana).
ADCS-CGIC scores <4 indicate improvement. 
Ocena <4 na lestvici ADCS-CGIC pomeni izboljšanje.
Administration of rivastigmine oral solution with food delays absorption (tmax) by 74 min and lowers Cmax by 43% and increases AUC by approximately 
Jemanje peroralne raztopine rivastigmina skupaj s hrano upočasni absorpcijo (tmax) za 74 minut, zmanjša Cmax za 43 % ter poveča AUC za okrog 9 %.
Also contains: polyethylene terephthalate film lacquered, alpha-tocopherol, poly(butylmethacrylate, methylmethacrylate), acrylic copolymer, silicone oil, dimethicone, polyester film fluoropolymercoated. 
Vsebuje tudi: lakiran polietilentereftalatni film, α-tokoferol, polimer (butilmetakrilat, metilmetakrilat), akrilni kopolimer, silikonsko olje, dimetikon, poliestrski film obložen s fluoro-polimerom.
Overdose with Prometax transdermal patch resulting from misuse/dosing errors (application of multiple patches at a time) has been reported in the post-marketing setting and rarely in clinical trials. 
V obdobju trženja zdravila so poročali o prevelikem odmerjanju s transdermalnimi obliži Prometax, do česar je prišlo zaradi nepravilne uporabe/odmerjanja (nameščenih več obližev hkrati) , v kliničnih študijah pa so o takih primerih poročali le redko.
Clinically relevant improvement was defined a priori as at least 4-point improvement on the ADAS-Cog, no worsening on the ADCS-CGIC, and no worsening on the ADCS-ADL. 
Klinično pomembno izboljšanje je bilo opredeljeno a priori kot izboljšanje na ADAS-Cog lestvici za vsaj 4 točke, brez poslabšanja v razvrstitvi ADCS-CGIC in brez poslabšanja na lestvici ADCS-ADL.
• Fits (seizures) 
• napadi krčev (epileptični napadi)
PC: [folding box only] SN: [folding box only] NN: [folding box only] 
EDINSTVENA OZNAKA - V BERLJIVI OBLIKI PC: [samo na škatli]
Parkinson's disease (worsening) Salivary hypersecretion Dyskinesia 
Parkinsonova bolezen (poslabšanje) Čezmerno izločanje sline
What Prometax is and what it is used for What you need to know before you use Prometax How to use Prometax 
Kaj je zdravilo Prometax in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili zdravilo Prometax Kako uporabljati zdravilo Prometax Možni neželeni učinki
Filling the syringe 
Polnjenje brizge
Patients with severe hepatic impairment have not been studied, however, Prometax oral solution may be used in this patient population provided close monitoring is exercised (see sections 4.4 and 5.2). 
Uporabe zdravila pri bolnikih s težko jetrno okvaro niso proučili, bolniki iz te populacije lahko kljub temu uporabljajo zdravilo Prometax peroralno raztopino, vendar jih je treba skrbno spremljati (glejte poglavji 4.4 in 5.2).
• Push the nozzle of the syringe into the hole in the white stopper. 
• Nastavek brizge vstavite v odprtino belega zamaška.
What Prometax looks like and contents of the pack Prometax oral solution is supplied as 50 ml or 120 ml of a clear, yellow solution (2.0 mg/ml base) in an amber glass bottle with a child-resistant cap, foam liner, dip tube and self aligning plug. 
Peroralna raztopina Prometax je na voljo v obliki 50 ml ali 120 ml bistre rumene raztopine (2,0 mg/ml baze), v jantarno obarvani steklenici z za otroke varno zaporko, oblogo iz penaste gume, s kapalnim vložkom in s prilegajočim se zamaškom.
There is no relevant use of Prometax in the paediatric population in the treatment of Alzheimer's disease. 
Zdravila Prometax ni smiselno uporabljati pri pediatrični populaciji za zdravljenje Alzheimerjeve bolezni.
What Prometax is and what it is used for What you need to know before you take Prometax How to take Prometax 
Kaj je zdravilo Prometax in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Prometax Kako jemati zdravilo Prometax Možni neželeni učinki
Prometax transdermal patches 9.5 mg/24 h N = 251 
Prometax transdermalni obliži 9,5 mg/24 h N = 251
ADAS-Cog LOCF 
ADAS-Cog metoda LOCF
In pregnant animals, rivastigmine and/or metabolites crossed the placenta. 
Pri brejih živalih so rivastigmin in/ali njegovi presnovki prehajali skozi posteljico.
colloidal anhydrous silica, gelatin, yellow iron oxide (E172), red iron oxide (E172), titanium dioxide (E171) and shellac. 
- Druge sestavine zdravila so hipromeloza, magnezijev stearat, mikrokristalna celuloza, koloidni silicijev dioksid, želatina, rumeni železov oksid (E172), rdeči železov oksid (E172), titanov dioksid (E171) in šelak.
• Feeling agitated 
• občutek vznemirjenosti
ITT + RDO population (n=329) 
Skupina ITT + RDO (n=329)
The active substance of Prometax is rivastigmine. 
Zdravilna učinkovina v zdravilu Prometax je rivastigmin.
Nightmares 
• nočne more
No pharmacokinetic interaction was observed between rivastigmine and digoxin, warfarin, diazepam or fluoxetine in studies in healthy volunteers. 
Med peroralnim rivastigminom in digoksinom, varfarinom, diazepamom ali fluoksetinom v študijah na zdravih prostovoljcih niso opazili farmakokinetičnega medsebojnega delovanja.
How to use Prometax 
Kako uporabljati zdravilo Prometax
Each ml contains 2 mg rivastigmine present as rivastigmine hydrogen tartrate. 
Vsak ml vsebuje 2 mg rivastigmina v obliki rivastigminijevega hidrogentartrata.
You may have side effects more often when you start your medicine or when your dose is increased. 
Neželeni učinki bodo morda pogostejši na začetku jemanja zdravila in ob zviševanju odmerka.
OUTER CARTON OF MULTIPACK (WITH BLUE BOX) 
ŠKATLICA ZA SKUPNO PAKIRANJE (VKLJUČNO Z "BLUE BOX" PODATKI)
Where to apply your Prometax transdermal patch 
Kam namestiti transdermalni obliž Prometax
1 transdermal patch of 15 cm contains 27 mg rivastigmine and delivers 13.3 mg/24 h. 
1 transdermalni obliž velikosti 15 cm vsebuje 27 mg rivastigmina in sprosti 13,3 mg/24 h.
ADCS-IADL LOCF 
ADCS-IADL metoda LOCF
Mean baseline ± SD Mean change at 24 weeks ± SD 
Povprečna sprememba po 24 tednih ± SD
Each Prometax 6.0 mg capsule contains 6.0 mg of rivastigmine. 
Vsaka kapsula Prometax 6,0 mg vsebuje 6,0 mg rivastigmina.
Each transdermal patch releases 4.6 mg of rivastigmine per 24 hours. 
Vsak transdermalni obliž sprosti 4,6 mg rivastigmina na 24 ur.
4.8 Undesirable effects 
4.8 Neželeni učinki Povzetek varnostnih lastnosti
Prometax 1.5 mg hard capsules Prometax 3.0 mg hard capsules Prometax 4.5 mg hard capsules Prometax 6.0 mg hard capsules 
Prometax 1,5 mg trde kapsule Prometax 3,0 mg trde kapsule Prometax 4,5 mg trde kapsule Prometax 6,0 mg trde kapsule
• Accidental falls 
• nezgodni padci
What Prometax contains - The active substance is rivastigmine. 
Kaj vsebuje zdravilo Prometax - Učinkovina je rivastigmin.
- The other ingredients are polyethylene terephthalate film lacquered, alpha-tocopherol, poly(butylmethacrylate, methylmethacrylate), acrylic copolymer, silicone oil, dimethicone, polyester film fluoropolymer-coated. 
- Druge sestavine zdravila so lakiran polietilen tereftalatni film, α-tokoferol, polimer (butilmetakrilat, metilmetakrilat), akrilni kopolimer, silikonsko olje, dimetikon, poliestrski film obložen s fluoro-polimerom.
Dose titration: Adverse reactions (e.g. hypertension and hallucinations in patients with Alzheimer's dementia and worsening of extrapyramidal symptoms, in particular tremor, in patients with dementia associated with Parkinson's disease) have been observed shortly after dose increase. 
Titriranje odmerka: V kratkem času po povečanju odmerka so opazili neželene učinke (npr. hipertenzijo in halucinacije pri bolnikih z Alzheimerjevo demenco in poslabšanje ekstrapiramidnih simptomov pri bolnikih z demenco v povezavi s Parkinsonovo boleznijo).
Gait disturbance 
Gibalne motnje
• Uneven heart rate (e.g. fast heart rate) 
• neredno bitje srca (npr. hitro bitje srca)
• Ulcers in your stomach or intestine 
• razjede želodca ali črevesja
ITT + RDO population (n=107) 
Skupina ITT + RDO (n=107)
What Prometax contains - The active substance is rivastigmine hydrogen tartrate. 
Kaj vsebuje zdravilo Prometax - Učinkovina je rivastigminijev hidrogentartrat.
1 transdermal patch of 10 cm contains 18 mg rivastigmine and delivers 9.5 mg/24 h. 
1 transdermalni obliž velikosti 10 cm vsebuje 18 mg rivastigmina in sprosti 9,5 mg/24 h.
Transdermal patch Novartis Pharma GmbH Roonstraße 25 
Transdermalni obliž Novartis Pharma GmbH Roonstraße 25
1 transdermal patch of 5 cm contains 9 mg rivastigmine and delivers 4.6 mg/24 h. 
1 transdermalni obliž velikosti 5 cm vsebuje 9 mg rivastigmina in sprosti 4,6 mg/24 h.
Prometax 1.5 mg hard capsules Prometax 3.0 mg hard capsules Prometax 4.5 mg hard capsules Prometax 6.0 mg hard capsules rivastigmine 
Prometax 1,5 mg trde kapsule Prometax 3,0 mg trde kapsule Prometax 4,5 mg trde kapsule Prometax 6,0 mg trde kapsule rivastigmin
• Ulcer in the intestine 
• razjeda v črevesju
Each Prometax 1.5 mg capsule contains 1.5 mg of rivastigmine. 
Vsaka kapsula Prometax 1,5 mg vsebuje 1,5 mg rivastigmina.
• Problems with your heartbeat such as slow heartbeat 
• motnje srčnega ritma, kot je prepočasen srčni utrip
Mean score  SD p-value versus placebo ADCS-ADL 
Povprečna ocena  SD Vrednost p proti placebu ADCS-ADL
Polyethylene terephthalate film, lacquered 
6.1 Seznam pomožnih snovi Krovna plast polietilen tereftalatni film, lakiran
Each transdermal patch of 15 cm contains 27 mg of rivastigmine. 
Vsak transdermalni obliž velikosti 15 cm vsebuje 27 mg rivastigmina.
Prometax 13.3 mg/24 h transdermal patches: Each patch releasing 13.3 mg of rivastigmine per 24 hours is 15 cm and contains 27 mg of rivastigmine. 
- Prometax 13,3 mg/24 h transdermalni obliži: vsak obliž, ki sprosti 13,3 mg rivastigmina na 24 ur, je velik 15 cm in vsebuje 27 mg rivastigmina.
- Prometax 4.6 mg/24 h transdermal patches: Each patch releasing 4.6 mg of rivastigmine per 24 hours is 5 cm and contains 9 mg of rivastigmine. 
- Prometax 4,6 mg/24 h transdermalni obliži: vsak obliž, ki sprosti 4,6 mg rivastigmina na 24 ur, je velik 5 cm in vsebuje 9 mg rivastigmina.
Each transdermal patch of 10 cm contains 18 mg of rivastigmine. 
Vsak transdermalni obliž velikosti 10 cm vsebuje 18 mg rivastigmina.
Each transdermal patch releases 9.5 mg of rivastigmine per 24 hours. 
Vsak transdermalni obliž sprosti 9,5 mg rivastigmina na 24 ur.
Other side effects seen with Prometax capsules or oral solution and which may occur with the patch: 
Drugi neželeni učinki, ki so jih opažali pri uporabi kapsul ali peroralne raztopine Prometax in bi se lahko pojavili tudi pri uporabi obližev:
- Prometax 9.5 mg/24 h transdermal patches: Each patch releasing 9.5 mg of rivastigmine per 24 hours is 10 cm and contains 18 mg of rivastigmine. 
- Prometax 9,5 mg/24 h transdermalni obliži: vsak obliž, ki sprosti 9,5 mg rivastigmina na 24 ur, je velik 10 cm in vsebuje 18 mg rivastigmina.
ADAS-cog scores: A negative difference in DLSM indicates greater improvement in Prometax 15 cm as compared to Prometax 10 cm 
DLSM - razlika po metodi najmanjših kvadratov (angl. difference in least square means) LOCF - metoda prenosa zadnje ocene naprej (angl. Last Observation Carried Forward) ocene pri lestvici ADAS-cog: negativna vrednost razlike po metodi najmanjših kvadratov pomeni večje izboljšanje pri uporabi obliža Prometax 15 cm kot pri uporabi obliža Prometax 10 cm ocene pri lestvici ADCS-IADL: pozitivna vrednost razlike po metodi najmanjših kvadratov pomeni večje izboljšanje pri uporabi obliža Prometax 15 cm kot pri uporabi obliža Prometax
The outside of the backing layer is beige and labelled with “Prometax”, “4.6 mg/24 h” and “AMCX”. 
Zunanji del krovne plasti je rjavkasto bele (beige) barve z oznakami “Prometax”, “4.6 mg/24 h” in “AMCX”.
Keep the transdermal patch in the sachet until use. 
Pred uporabo shranjujte transdermalni obliž v vrečki.
Each transdermal patch of 5 cm contains 9 mg of rivastigmine. 
Vsak transdermalni obliž velikosti 5 cm vsebuje 9 mg rivastigmina.
You should not breast-feed during treatment with Prometax transdermal patches. 
Med zdravljenjem s transdermalnimi obliži Prometax ne smete dojiti.
Application site skin reactions (usually mild to moderate application site erythema), are the most frequent adverse reactions observed with the use of Prometax transdermal patch. 
Med neželenimi učinki, ki so jih opažali pri uporabi transdermalnega obliža Prometax, so najbolj pogoste kožne reakcije na mestu apliciranja (običajno blaga do zmerna rdečina kože na mestu apliciranja).
Always use Prometax transdermal patches exactly as your doctor has told you. 
Pri uporabi transdermalnih obližev Prometax natančno upoštevajte navodila zdravnika.
Rivastigmine in vivo release rates per 24 h 
Odmerjanje transdermalni obliži hitrost sproščanja rivastigmina na 24 ur in vivo
One of the excipients in Prometax oral solution is sodium benzoate. 
Ena od pomožnih snovi peroralne raztopine Prometax je natrijev benzoat.
• Stomach ulcer 
• želodčna razjeda
CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 
VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ENOT 1 transdermalni obliž na vrečko
Each transdermal patch releases 13.3 mg of rivastigmine per 24 hours. 
Vsak transdermalni obliž sprosti 13,3 mg rivastigmina na 24 ur.
• Changes in how well your liver is working 
• spremembe v delovanju jeter
Each Prometax 4.5 mg capsule contains 4.5 mg of rivastigmine. 
Vsaka kapsula Prometax 4,5 mg vsebuje 4,5 mg rivastigmina.
When and for how long to apply your Prometax transdermal patch 
Kdaj namestiti transdermalni obliž Prometax in za koliko časa
Prometax should not be given at the same time as metoclopramide (a medicine used to relieve or prevent nausea and vomiting). 
Zdravila Prometax ne smete jemati sočasno z metoklopramidom (zdravilom, ki ga uporabljamo za ublažitev ali preprečevanje navzee (slabosti s siljenjem na bruhanje) in bruhanja).
How to take Prometax 
Kako jemati zdravilo Prometax
No specific interaction studies have been performed with Prometax transdermal patches. 
Pri osebah z okvaro ledvic niso opravili nobene študije s transdermalnimi obliži Prometax.
Each Prometax 3.0 mg capsule contains 3.0 mg of rivastigmine. 
Vsaka kapsula Prometax 3,0 mg vsebuje 3,0 mg rivastigmina.
Poly(butylmethacrylate, methylmethacrylate) Acrylic copolymer 
Matriks zdravila α-tokoferol polimer (butilmetakrilat, metilmetakrilat) akrilni kopolimer
• A patient on a dose of 12 mg/day oral rivastigmine can be switched to 9.5 mg/24 h transdermal patches. 
• Bolnik, ki jemlje rivastigmin peroralno v odmerku 12 mg/dan, lahko preide na zdravljenje s transdermalnimi obliži 9,5 mg/24 h.
Worsening (including bradykinesia, dyskinesia, gait abnormality) and an increased incidence or severity of tremor have been observed in patients with dementia associated with Parkinson's disease (see section 4.8). 
Pri bolnikih z demenco v povezavi s Parkinsonovo boleznijo so opazili poslabšanje (ki vključuje bradikinezijo, diskinezijo in motnje drže) in povečano pojavnost in intenzivnost tremorja (glejte poglavje 4.8).
Prometax 4.6 mg/24 h transdermal patch Prometax 9.5 mg/24 h transdermal patch Prometax 13.3 mg/24 h transdermal patch rivastigmine 
Prometax 4,6 mg/24 h transdermalni obliž Prometax 9,5 mg/24 h transdermalni obliž Prometax 13,3 mg/24 h transdermalni obliž rivastigmin
Hepatitis, elevated liver function tests Skin and subcutaneous tissue disorders Common 
Bolezni jeter, žolčnika in žolčevodov občasni zvišani jetrni funkcijski testi pogostnost neznana hepatitis
The outside of the backing layer is beige and labelled with “Prometax”, “9.5 mg/24 h” and “BHDI”. 
Zunanji del krovne plasti je rjavkasto bele (beige) barve z oznakami “Prometax”, “9.5 mg/24 h” in “BHDI”.
Prometax 4.6 mg/24 h transdermal patch Prometax 9.5 mg/24 h transdermal patch Prometax 13.3 mg/24 h transdermal patch 
Prometax 4,6 mg/24 h transdermalni obliž Prometax 9,5 mg/24 h transdermalni obliž Prometax 13,3 mg/24 h transdermalni obliž
The outside of the backing layer is beige and labelled with “Prometax”, “13.3 mg/24 h” and “CNFU”. 
Zunanji del krovne plasti je rjavkasto bele (beige) barve z oznakami “Prometax”, “13.3 mg/24 h” in “CNFU”.
Prometax transdermal patches 9.5 mg/24 h 
Prometax transdermalni obliži 9,5 mg/24 h
Prometax 2 mg/ml oral solution rivastigmine 
Prometax 2 mg/ml peroralna raztopina rivastigmin
• Heartburn 
• tesnoba
• A patient on a dose of 3 mg/day oral rivastigmine can be switched to 4.6 mg/24 h transdermal patches. 
• Bolnik, ki jemlje rivastigmin peroralno v odmerku 3 mg/dan, lahko preide na zdravljenje s transdermalnimi obliži 4,6 mg/24 h.
• Some people who have been violently sick have had tearing of the tube that connects your mouth with your stomach (oesophagus) 
• pri nekaterih ljudeh je zaradi močnega bruhanja prišlo do raztrganja požiralnika (cevi, ki leži med usti in želodcem)
• A patient on a dose of 6 mg/day oral rivastigmine can be switched to 4.6 mg/24 h transdermal patches. 
• Bolnik, ki jemlje rivastigmin peroralno v odmerku 6 mg/dan, lahko preide na zdravljenje s transdermalnimi obliži 4,6 mg/24 h.
The patient's weight should be monitored during therapy with Prometax transdermal patches. 
Med zdravljenjem s transdermalnimi obliži Prometax je treba spremljati bolnikovo telesno maso.
Caution when Prometax is taken together with beta-blockers (medicines such as atenolol used to treat hypertension, angina and other heart conditions). 
Previdnost je potrebna pri sočasni uporabi zdravila Prometax in katerega od antagonistov adrenergičnih receptorjev beta (učinkovin, kot je atenolol, ki ga uporabljamo za zdravljenje visokega krvnega tlaka, angine pektoris in drugih bolezni srca).
Caution when Prometax Patch is given together with beta-blockers (medicines such as atenolol used to treat hypertension, angina, and other heart conditions). 
Previdnost je potrebna pri sočasni uporabi zdravila Prometax obliži in katerega od antagonistov adrenergičnih receptorjev beta (učinkovin, kot je atenolol, ki ga uporabljamo za zdravljenje visokega krvnega tlaka, angine pektoris in drugih bolezni srca).
Each capsule contains rivastigmine hydrogen tartrate corresponding to 1.5 mg rivastigmine. 
Vsaka kapsula vsebuje rivastigminijev hidrogentartrat v količini, ki ustreza 1,5 mg rivastigmina.
Each capsule contains rivastigmine hydrogen tartrate corresponding to 6.0 mg rivastigmine. 
Vsaka kapsula vsebuje rivastigminijev hidrogentartrat v količini, ki ustreza 6,0 mg rivastigmina.